About Quidel Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California. Address: 9975 Summers Ridge Road, San Diego, CA, United States, 92121
Quidel Corporation News and around…
Latest news about Quidel Corporation (QDEL) common stock and company :
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Quidel Corporation...
According to Benzinga Pro, during Q1, Quidel (NASDAQ:QDEL) earned $479.94 million, a 64.75% increase from the preceding quarter. Quidel ...
Quidel Corporation (Nasdaq: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc (“Ortho”) by Quidel and subsequent business combination were approved by Quidel’s stockholders at Quidel’s Special Meeting on May 16, 2022.
RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho” or the “Company”), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ: QDEL) (“Quidel”) pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Com
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Guardant Health Inc (GH), where a total of 10,391 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 59.1% of GH's average daily trading volume over the past month of 1.8 million shares..
Quidel's (QDEL) robust performance across two of its product categories drives its first-quarter 2022 top line.
Quidel Corp's(NASDAQ: QDEL)Q1 sales more than doubled to $1 billion, beating the consensus of $890 million ...
Quidel (QDEL) delivered earnings and revenue surprises of 25.65% and 21.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Quidel (NASDAQ:QDEL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:10 PM. Here's what investors need to know about ...
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2022.
The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.
With its stock down 11% over the past month, it is easy to disregard Quidel (NASDAQ:QDEL). However, a closer look at...
Quidel's (QDEL) first-quarter results are likely to reflect continued strength across its SARS-related products.
Quidel (QDEL) closed at $104.52 in the latest trading session, marking a -1.32% move from the prior day.
In the latest trading session, Quidel (QDEL) closed at $113.95, marking a +1.29% move from the previous day.
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2022 financial results after market close on Wednesday, May 4, 2022.
In the latest trading session, Quidel (QDEL) closed at $112.50, marking a -0.51% move from the previous day.
Quidel's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued robust sales of its SARS-related products.
Investors in Quidel Corp. (QDEL) saw new options begin trading this week, for the May 20th expiration..
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR Portfolio S&P 400 Mid Cap ETF (SPMD), we found that the implied analyst target price for the ETF based upon its underlying holdings is $56.55 per unit.
After several extremely volatile days, US equity futures are ending the week in the green with European equities snapping two days of declines sparked by the Fed's plan for aggressive monetary-policy tightening, and Asian stocks trading higher.
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Harpoon Announces Departure ...
Quidel Corp(NASDAQ: QDEL)expects Q1 FY22 sales of $990 million - $1 billion, up 164% - 166% Y/Y, beating the consensus of ...
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects total revenues in the first quarter of 2022 to be in the range of $990 million to $1,000 million, or growth of 164% to 166% from the first quarter 2021 revenue of $375.3 million. COVID-19 product revenues in the first quarter of 2022 are expected to be approximately $836 million, composed of approximately $657 million in QuickVue® COVID-19 test revenue and approximately $138 million in Sofia® SARS antigen test revenue.
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
By avoiding memes and sticking to a long-term strategy, you can minimize your portfolio's risk.
Quidel (QDEL) closed the most recent trading day at $112.46, moving -0.3% from the previous trading session.
Encompass Health (EHC) opens a 60-bed inpatient rehabilitation hospital in Illinois, sustaining its aim to offer enhanced rehabilitation services throughout the United States.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Mid Cap ETF (AFMC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $29.18 per unit.
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed ...